Nasdaq4d
Corbus Pharmaceuticals Announces Release of CRB-701 Clinical Study Abstract Ahead of ASCO GU Symposium
Corbus Pharmaceuticals Holdings, Inc. has announced the release of an abstract for its first-in-human dose escalation clinical study of CRB-701 (SYS6002), which targets Nectin-4 in patients with ...
Business Insider2d
Analysts Have Conflicting Sentiments on These Healthcare Companies: Corbus Pharmaceuticals (CRBP), Genmab (GMAB) and CVRx (CVRX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corbus Pharmaceuticals (CRBP – Research Report), Genmab (GMAB – Research Report) and CVRx (CVRX ...
Business Insider4d
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the ...
ETF Daily News3d
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives $62.00 Consensus PT from Analysts
Corbus Pharmaceuticals has a 12 month low of $8.74 and a 12 month high of $61.90. The stock has a fifty day moving average price of $12.49 and a 200-day moving average price of $26.68. Corbus ...